NEWTON,
Mass., Dec. 9, 2024 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced the
appointment of Brendan Strong as
Senior Vice President of Investor Relations and Corporate
Communications.
"We are thrilled to have Brendan on board as we work towards
delivering on and communicating important milestones for our
organization in 2025," said Richard
Paulson, President and Chief Executive Officer of
Karyopharm. "Brendan's experience as a former sell-side analyst,
advisor to biopharmaceutical companies and proven ability to
develop strong investor relations and corporate communications
programs will serve us well as we look to execute on the
opportunities ahead of us."
"I am excited by the opportunities that Karyopharm has to
positively impact the lives of patients through our late-stage
pipeline, building on our core foundation in multiple myeloma,"
said Brendan Strong, Senior Vice
President of Investor Relations and Corporate
Communications. "The upcoming year represents a transformative
time for our organization and I look forward to advancing our
mission."
Most recently, Brendan served as Managing Director at Argot
Partners where he advised biopharmaceutical companies on their
investor relations and corporate communications programs.
Previously, Brendan led investor relations for Tenet Healthcare and
also served as Chief Financial Officer of Tenet's Massachusetts
Market. Earlier in his career, he worked in the equity research
department at Lehman Brothers and Barclays and also participated in
a financial leadership training program at AT&T.
Brendan earned an MBA from Harvard Business
School and a B.S. in Finance from Rutgers University.
About Karyopharm Therapeutics
Karyopharm Therapeutics
Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company
whose dedication to pioneering novel cancer therapies is fueled by
a belief in the extraordinary strength and courage of patients with
cancer. Since its founding, Karyopharm has been an industry leader
in oral compounds that address nuclear export dysregulation, a
fundamental mechanism of oncogenesis. Karyopharm's lead compound
and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO®
(selinexor), is approved in the U.S. and marketed by the Company in
three oncology indications. It has also received regulatory
approvals in various indications in a growing number of ex-U.S.
territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline
targeting indications in multiple high unmet need cancers,
including in multiple myeloma, endometrial cancer, myelofibrosis,
and diffuse large B-cell lymphoma (DLBCL). For more information
about our people, science and pipeline, please visit
www.karyopharm.com, and follow us on LinkedIn and on X at
@Karyopharm.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include those regarding Karyopharm's clinical
development plans and potential regulatory submissions of selinexor
and the ability of selinexor to treat patients with multiple
myeloma, endometrial cancer, myelofibrosis, diffuse large B-cell
lymphoma, and other diseases. Such statements are subject to
numerous important factors, risks and uncertainties, many of which
are beyond Karyopharm's control, that may cause actual events or
results to differ materially from Karyopharm's current
expectations. For example, there can be no guarantee that
Karyopharm will successfully commercialize XPOVIO or that any of
Karyopharm's drug candidates, including selinexor, will
successfully complete necessary clinical development phases or that
development of any of Karyopharm's drug candidates will continue.
Further, there can be no guarantee that any positive developments
in the development or commercialization of Karyopharm's drug
candidate portfolio will result in stock price appreciation.
Management's expectations and, therefore, any forward-looking
statements in this press release could also be affected by risks
and uncertainties relating to a number of other factors, including
the following: the adoption of XPOVIO in the commercial
marketplace, the timing and costs involved in commercializing
XPOVIO or any of Karyopharm's drug candidates that receive
regulatory approval; the ability to obtain and retain regulatory
approval of XPOVIO or any of Karyopharm's drug candidates that
receive regulatory approval; Karyopharm's results of clinical
trials and preclinical trials, including subsequent analysis of
existing data and new data received from ongoing and future trials;
the content and timing of decisions made by the U.S. Food and Drug
Administration and other regulatory authorities, investigational
review boards at clinical trial sites and publication review
bodies, including with respect to the need for additional clinical
trials; the ability of Karyopharm or its third party collaborators
or successors in interest to fully perform their respective
obligations under the applicable agreement and the potential future
financial implications of such agreement; Karyopharm's ability to
enroll patients in its clinical trials; unplanned cash requirements
and expenditures; substantial doubt exists regarding Karyopharm's
ability to continue as a going concern; development or
regulatory approval of drug candidates by Karyopharm's competitors
for products or product candidates in which Karyopharm is currently
commercializing or developing; the direct or indirect impact of the
COVID-19 pandemic or any future pandemic on Karyopharm's business,
results of operations and financial condition; and Karyopharm's
ability to obtain, maintain and enforce patent and other
intellectual property protection for any of its products or product
candidates. These and other risks are described under the caption
"Risk Factors" in Karyopharm's Quarterly Report on Form 10-Q for
the quarter ended September 30, 2024,
which was filed with the Securities and Exchange Commission (SEC)
on November 5, 2024, and in other
filings that Karyopharm may make with the SEC in the future. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and, except as required by law,
Karyopharm expressly disclaims any obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
XPOVIO® and NEXPOVIO® are registered
trademarks of Karyopharm Therapeutics Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-announces-the-appointment-of-brendan-strong-as-senior-vice-president-of-investor-relations-and-corporate-communications-302326036.html
SOURCE Karyopharm Therapeutics Inc.